Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 8 July 2008, doi:10.1136/bmj.a708
Cite this as: BMJ 2008;337:a708
Janice Hopkins Tanne
1 New York
| The first 150 words of the full text of this article appear below. |
Pfizer, the worlds second largest drug company, said last week that it would no longer pay profit making communication and medical education companies to provide continuing medical education courses. It will continue to pay for education prepared by non-profit organisations, academic institutions, teaching hospitals, and medical societies.
Pfizer said it was making the change to avoid the appearance of having conflicts of interest, because critics had said that courses supported by the industry were not purely educational but promoted the use of specific drugs.
US doctors are required to complete a certain number of hours of continuing medical education courses to keep their medical licences current.
Pfizers press release quoted Dave Davis, vice president for continuing education and improvement at the Association of American Medical Colleges, who said, "This move by Pfizer, to my knowledge the first among commercial supporters of CME [continuing medical education], represents a significant advance in
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
StumbleUpon
Technorati What's this?